Figure 6 Effects of adiponectin on podocyte function

Slides:

Advertisements

Similar presentations

Figure 1 Schematic representation of idiopathic nephrotic syndrome,

Advertisements

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 The theoretical contribution of genetic and

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 3 Angiotensin signalling in adiporenal crosstalk

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Proinflammatory mechanisms in CKD

Figure 3 The fat–intestine–kidney axis

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 BMI and mortality in patients with heart failure

Figure 1 Pathologic features of obesity-related glomerulopathy (ORG)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 5 Comparison of outcomes with belimumab or rituximab therapy

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Figure 1 Acute kidney injury and chronic kidney disease

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Figure 2 Prevention of antigen–antibody

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Specificity of the various epidermal growth factor (EGF)

Figure 2 Organ crosstalk in the pathophysiology

and obesity-related kidney diseases

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Potential mechanisms of PAR activation by thrombin and aPC

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Loss of the glycocalyx leads to podocyte and kidney injury

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Figure 4 Podocyte–endothelial cross talk and activation of heparanase

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Mechanisms of crosstalk between adipocytes and the kidney

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Figure 4 Intracellular distribution and

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Mechanisms of adiponectin actions in the kidney

Volume 76, Issue 2, Pages (July 2009)

Presentation transcript:

Figure 6 Effects of adiponectin on podocyte function Figure 6 | Effects of adiponectin on podocyte function. Increased adipose mass leads to decreased levels of adiponectin and reduced activation of the adiponectin receptor on podocytes, reduced AMPK activation and increased inflammation. In mice, lack of adiponectin leads to foot process effacement and albuminuria. The early onset of albuminuria in patients with obesity and hypertension might also be associated with reduced adiponectin levels. Câmara, N. O. S. et al. (2017) Kidney disease and obesity: epidemiology, mechanisms and treatment Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.191